Optimizing yeast for high-level production of kaempferol and quercetin.


Journal

Microbial cell factories
ISSN: 1475-2859
Titre abrégé: Microb Cell Fact
Pays: England
ID NLM: 101139812

Informations de publication

Date de publication:
20 Apr 2023
Historique:
received: 11 03 2023
accepted: 09 04 2023
medline: 21 4 2023
pubmed: 20 4 2023
entrez: 19 04 2023
Statut: epublish

Résumé

Two important flavonoids, kaempferol and quercetin possess remarkably potent biological impacts on human health. However, their structural complexity and low abundance in nature make both bulk chemical synthesis and extraction from native plants difficult. Therefore microbial production via heterologous expression of plant enzymes can be a safe and sustainable route for their production. Despite several attempts reported in microbial hosts, the production levels of kaempferol and quercetin still stay far behind compared to many other microbial-produced flavonoids. In this study, Saccharomyces cerevisiae was engineered for high production of kaempferol and quercetin in minimal media from glucose. First, the kaempferol biosynthetic pathway was reconstructed via screening various F3H and FLS enzymes. In addition, we demonstrated that amplification of the rate-limiting enzyme AtFLS could reduce the dihydrokaempferol accumulation and improve kaempferol production. Increasing the availability of precursor malonyl-CoA further improved the production of kaempferol and quercetin. Furthermore, the highest amount of 956 mg L De novo biosynthesis of kaempferol and quercetin in yeast was improved through increasing the upstream naringenin biosynthesis and debugging the flux-limiting enzymes together with fed-batch fermentations, up to gram per liter level. Our work provides a promising platform for sustainable and scalable production of kaempferol, quercetin and compounds derived thereof.

Sections du résumé

BACKGROUND BACKGROUND
Two important flavonoids, kaempferol and quercetin possess remarkably potent biological impacts on human health. However, their structural complexity and low abundance in nature make both bulk chemical synthesis and extraction from native plants difficult. Therefore microbial production via heterologous expression of plant enzymes can be a safe and sustainable route for their production. Despite several attempts reported in microbial hosts, the production levels of kaempferol and quercetin still stay far behind compared to many other microbial-produced flavonoids.
RESULTS RESULTS
In this study, Saccharomyces cerevisiae was engineered for high production of kaempferol and quercetin in minimal media from glucose. First, the kaempferol biosynthetic pathway was reconstructed via screening various F3H and FLS enzymes. In addition, we demonstrated that amplification of the rate-limiting enzyme AtFLS could reduce the dihydrokaempferol accumulation and improve kaempferol production. Increasing the availability of precursor malonyl-CoA further improved the production of kaempferol and quercetin. Furthermore, the highest amount of 956 mg L
CONCLUSIONS CONCLUSIONS
De novo biosynthesis of kaempferol and quercetin in yeast was improved through increasing the upstream naringenin biosynthesis and debugging the flux-limiting enzymes together with fed-batch fermentations, up to gram per liter level. Our work provides a promising platform for sustainable and scalable production of kaempferol, quercetin and compounds derived thereof.

Identifiants

pubmed: 37076829
doi: 10.1186/s12934-023-02084-4
pii: 10.1186/s12934-023-02084-4
pmc: PMC10116799
doi:

Substances chimiques

Quercetin 9IKM0I5T1E
Kaempferols 0
Flavonoids 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

74

Informations de copyright

© 2023. The Author(s).

Références

Microb Cell Fact. 2017 Sep 26;16(1):165
pubmed: 28950867
FEMS Yeast Res. 2015 Mar;15(2):
pubmed: 25743786
Cancer Lett. 2000 Aug 11;156(2):117-24
pubmed: 10880760
Acta Biochim Biophys Sin (Shanghai). 2014 Jun;46(6):460-70
pubmed: 24760952
ScientificWorldJournal. 2013 Dec 29;2013:162750
pubmed: 24470791
Nat Commun. 2019 Oct 31;10(1):4976
pubmed: 31672987
Metab Eng. 2009 Nov;11(6):355-66
pubmed: 19631278
Microbiol Res. 1997 Sep;152(3):239-46
pubmed: 9352659
J Biotechnol. 2017 Sep 20;258:190-196
pubmed: 28143765
Nat Prod Rep. 2009 Aug;26(8):1001-43
pubmed: 19636448
Biotechniques. 2010 Jun;48(6):463-5
pubmed: 20569222
Methods Enzymol. 2002;350:87-96
pubmed: 12073338
ACS Synth Biol. 2021 May 21;10(5):1166-1175
pubmed: 33877810
Nat Methods. 2009 May;6(5):343-5
pubmed: 19363495
Biotechnol Bioeng. 2006 Oct 20;95(3):433-45
pubmed: 16736531
Mutagenesis. 2002 Jan;17(1):45-53
pubmed: 11752233
Metab Eng. 2012 Mar;14(2):104-11
pubmed: 22326477
Bioinformatics. 2015 Apr 1;31(7):1120-3
pubmed: 25414360
Biochem Pharmacol. 2006 Oct 16;72(8):1010-21
pubmed: 16934226
mBio. 2014 May 06;5(3):e01130-14
pubmed: 24803522
Front Microbiol. 2017 Nov 16;8:2259
pubmed: 29201020
Mini Rev Med Chem. 2011 Feb;11(2):169-77
pubmed: 21222576
Pharmacogn Rev. 2016 Jul-Dec;10(20):84-89
pubmed: 28082789
J Nutr Biochem. 2006 Mar;17(3):165-76
pubmed: 16169200
J Agric Food Chem. 2020 Jun 24;68(25):6884-6891
pubmed: 32458684
Biotechnol Adv. 2016 Sep-Oct;34(5):634-662
pubmed: 26946281
Int Immunopharmacol. 2012 Jan;12(1):139-43
pubmed: 22116056
Am J Clin Nutr. 2012 Apr;95(4):925-33
pubmed: 22357723
Appl Microbiol Biotechnol. 2006 Jun;71(1):53-8
pubmed: 16133333
ACS Synth Biol. 2023 Jan 20;12(1):144-152
pubmed: 36534476
Yeast. 1992 Jul;8(7):501-17
pubmed: 1523884
Plant Foods Hum Nutr. 2004 Summer;59(3):113-22
pubmed: 15678717
Planta Med. 2014 Feb;80(2-3):177-82
pubmed: 24458263
Int J Antimicrob Agents. 2005 Nov;26(5):343-56
pubmed: 16323269
Int J Antimicrob Agents. 2011 Aug;38(2):99-107
pubmed: 21514796
PLoS One. 2018 May 17;13(5):e0197563
pubmed: 29771951
Bioresour Technol. 2017 Dec;245(Pt B):1645-1654
pubmed: 28634125
Food Chem. 2013 Jun 15;138(4):2099-107
pubmed: 23497863
J Agric Food Chem. 2019 May 15;67(19):5596-5606
pubmed: 30957490
Metab Eng. 2020 Jan;57:174-181
pubmed: 31740389
PLoS One. 2018 Nov 15;13(11):e0207278
pubmed: 30440014

Auteurs

Musa Tartik (M)

Department of Molecular Biology and Genetics, Faculty of Arts and Sciences, Bingol University, Bingol, 12000, Turkey.
Department of Life Sciences, Chalmers University of Technology, Kemivägen 10, Gothenburg, SE-412 96, Sweden.

Juan Liu (J)

Department of Life Sciences, Chalmers University of Technology, Kemivägen 10, Gothenburg, SE-412 96, Sweden.

Marta Tous Mohedano (MT)

Department of Life Sciences, Chalmers University of Technology, Kemivägen 10, Gothenburg, SE-412 96, Sweden.

Jiwei Mao (J)

Department of Life Sciences, Chalmers University of Technology, Kemivägen 10, Gothenburg, SE-412 96, Sweden.

Yun Chen (Y)

Department of Life Sciences, Chalmers University of Technology, Kemivägen 10, Gothenburg, SE-412 96, Sweden. yunc@chalmers.se.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH